SYNTHBODY(TM) introduces a new class of "smart drugs": protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a ...

Rational design, applying knowledge structure-function relationships into molecular design, has shown great promise in enzyme engineering, vaccine development, and inhibitor discovery. Using rational ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent, the AI-first protein design company, today announced Protein2PAM, the first in a series of AI models that will broadly focus on protein-DNA interactions ...

Artificial intelligence is rapidly learning to autonomously design and run biological experiments, but the systems intended to govern those capabilities are struggling to keep pace. AI company OpenAI ...

AI is accelerating protein design by enhancing structure prediction, candidate screening, and downstream analysis, enabling faster and more consistent results. Automation complements these advances by ...

Dr. Simon Sumer explains how AI‑driven protein design is shortening development cycles, improving screening efficiency, and ...

Artificial intelligence is already proving it can accelerate drug development and improve our understanding of disease. But ...

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in ...

SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that ...

Within each individual’s immune system is a unique repertoire of billions of T cells patrolling the body to uncover and eliminate foreign threats. Yet this army is not foolproof and can miss the ...

A new way to potentially control when drugs are active or inactive in the body is introduced in a study reported Sept. 24 in Nature. The research showed that, instead of controlling how tightly ...